MRI Diagnostic for Differentiating Low-Grade Bladder Cancers
MONDAY, Jan. 29, 2018 -- Magnetic resonance (MR) imaging is accurate in differentiating T1 or lower tumors from T2 or higher tumors among patients with bladder cancer, according to a review published in the February issue of Radiology.
Li Huang, M.D., Ph.D., from Sun Yat-Sen University in Guangzhou, China, and colleagues conducted a systematic literature review to identify studies evaluating the diagnostic accuracy of MR imaging for differentiating stage T1 or lower tumors from stage T2 or higher tumors in patients with bladder cancer. Additionally, studies assessing the influence of different imaging protocols in patients with bladder cancer were examined.
The researchers identified 17 studies totaling 1,449 patients with bladder cancer. Across studies, the pooled sensitivity of MR imaging was 0.90 and the specificity was 0.88 for differentiating tumors staged T1 or lower from those staged T2 or higher. Sensitivity (0.92) and specificity (0.96) were improved with diffusion-weighted imaging and use of higher field strengths (3 T).
"Our meta-analysis shows high sensitivity and specificity for MR imaging to differentiate T1 or lower tumors from T2 or higher tumors before surgery and that a 3.0-T device combined with diffusion-weighted imaging had the highest sensitivity and specificity in all studies," the authors write.
© 2020 HealthDay. All rights reserved.
Posted: January 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.